ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Are you interested in receiving our latest news? Simply fill out the form below to receive news alerts directly to your inbox. To receive releases from a specific CSL business unit, select customize ...

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.